Abstract: Objective To observe the clinical efficacy of a comprehensive regimen combining recombinant human vascular endothelial inhibitor with doxorubicin in arterial intervention therapy for the treatment of colorectal cancer liver metastases. Methods In this study, 110 patients with colorectal cancer liver metastasis who were diagnosed from February 2020 to May 2022 were selected and divided into two groups by using an odd-even grouping method. The control group was given arterial intervention treatment with doxorubicin comprehensive therapy, and the observation group was combined with recombinant human vascular endothelial inhibitor treatment. The differences in Golgi protein 73 (GP73), carcinoembryonic antigen (CEA), omentin-1, and cytokeratin 19 fragment (CYFRA21-1) were compared between the two groups, and the overall quality of survival was assessed, and the immediate and long-term efficacy of the two groups was recorded. Results There was no statistical difference in GP73, CEA, Omentin-1 and CYFRA21-1 levels in these two groups before treatment (P>0.05). The levels significantly decreased in both groups after treatment (P<0.05), and was significantly lower in the observation group when compared with those of the control group (P<0.05). The overall Karnofsky Performance Status (KPS) score of the observation group was better than that of the control group (P<0.05). All patients had grade 1-2 toxic side effects, and no grade 3-4 toxic side effects occurred. There was no statistical difference in the incidence of anemia, thrombocytopenia, neutropenia, diarrhea, elevated AST or ALT, elevated blood pressure, nausea and vomiting between the two groups (P>0.05). The recent Objective remission rate (ORR) of 61.82% (34/55) in the observation group was higher than that of 41.82% (23/55) in the control group, which was statistically different (P<0.05).The follow-up of patients ended in August 2023, with a follow-up period of 4~18 months and a median follow-up period of 10.47 months, with a median progression-free survival time of 4.5 months in the control group and 7.7 months in the observation group. Conclusion A comprehensive regimen of arterial intervention with doxorubicin in combination of recombinant human vascular endothelial inhibitor for the treatment of colorectal cancer liver metastases inhibits the expression of GP73, CEA, and other factors, improves immediate and long-term efficacy,without increasing the risk of adverse effects.

Key words: Recombinant human vascular endothelial inhibitor, Doxorubicin, Arterial intervention, Colorectal cancer, Liver metastasis